Signals 01: November 2025
Introducing Signals: A new collaboration with Neurofounders
Signals is a new market insights offering for Neurotech leaders
With more companies, accelerating investments, and growing attention from all sides, the global neurotech landscape is getting noisier every day, making it harder to discern which developments really matter and why.
Neurotech Futures is teaming up with Neurofounders to cut through the noise with dedicated, timely analysis for today’s c-suite leaders and commercial operators.
Neurofounders has emerged as our industry’s TechCrunch, with fast but nuanced coverage of breaking news along with a growing ecosystem of resources.
I’m thrilled to be partnering with Neurofounders editor-in-chief Dominic Borkelmans, who has quickly become the most prolific neurotech industry writer in the world today.
Together, we’ll personally distill and deliver analysis of the emerging signals of commercial success in neurotech that you need to know about today.
Signals is exclusively available through Neurotech Futures’ paid membership.
Monthly Digest: Each month you’ll get an executive memo covering the prior month’s key deals, with context and analysis to guide your strategy.
Inform Coverage: Let us know which deals, trends, or stories need to be explored, covered, or uncovered for leaders navigating the frontier.
Watch This Space for exclusive early access to opportunities for collaboration on public programming, paid content, and more.
Perks on Perks: Members will keep getting Insider bulletins, all archived Notables and paid content, plus new perks next year at no extra cost.
We’ll be moving fast into 2026 - join us today so you don’t miss a thing!
Signals 01: November 2025
November was a torrid month across neurotech. Here’s what caught our eye:
Beacon and Cognision validate the life sciences x neurotech pipeline
Coherence, Cordance, and Neurotech’s Cancer Frontier*
BCI x AI: INBRAIN leads on Agentic AI with Microsoft partnership
UNESCO recommends ethical guardrails around neural data; a sign of more to come?
Synchron raises $200m, bolstering confidence in minimally invasive BCI
Cognito partners with WVU and lays groundwork for meaningful adoption
Paradromics moves into clinical trials, kicking off the commercial era for speech restoration BCI
Phantom Neuro opens patient registry, making progress on an underrepresented opportunity
Nyxoah’s financing & CMS approval build commercial momentum
 | A guest post by
|